Nanexa invites to a webcast to present the positive clinical data from NEX-22 once monthly GLP-1, liraglutide project published on last Friday

Referring to the clinical results presented last Friday Nanexa invites to a webcast hosted by Infront Direkt studios at 14:00 pm today, Monday November 25th.

Chairman Dr. Göran Ando, CEO David Westberg and Director Business Development Otto Skolling will present the results as well as an overview of the GLP-1 segment and plans going forward.
“These clinical results put us in a completely new, very exciting situation with a potential to transform the type-2 diabetes and obesity treatment regime to less frequent treatments say David Westberg, CEO Nanexa.”

The comment will be available here.
Viewers will have the opportunity to ask questions via chat.

The comment will also be published on Nanexa's website afterwards.

Datum 2024-11-25, kl 08:00
Källa MFN
100% cashback på aktiecourtage! Handla aktier på eToro och få tillbaka 100% av ditt courtage i 3 månader. Hur? Registrera dig här nu direkt för att ta del av erbjudandet.
Cashback är begränsad till högst $100. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.